Health Econ Rev. 2013 Dec 05;3(1):28. doi: 10.1186/2191-1991-3-28.

Cost-effectiveness analysis of azacitidine in the treatment of high-risk myelodysplastic syndromes in Spain.

Health economics review

Carlos Crespo, Estela Moreno, Jordi Sierra, Suzan Serip, Marta Rubio

PMID: 24314138 PMCID: PMC4029489 DOI: 10.1186/2191-1991-3-28

Abstract

BACKGROUND: The objective of the study was to analyse whether azacitidine is a cost-effective option for the treatment of myelodysplastic syndrome in the Spanish setting compared with conventional care regimens, including best supportive care, low dose chemotherapy and standard dose chemotherapy.

METHODS: A life-time Markov model was constructed to evaluate the cost-effectiveness of azacitidine compared with conventional care regimens. The health states modelled were: myelodysplastic syndrome, acute myeloid leukemia and death. Variables measured included survival rates, progression probabilities and quality of life indicators. Resource use and cost data reflect the Spanish context. The analysis was performed from the Spanish National Health System perspective, discounting both costs (in 2012 euros) and future effects at 3%. The time horizon considered was end-of-life. Results were expressed in cost per quality-adjusted life-year gained and cost per life-year gained and compared with cost-effectiveness thresholds.

RESULTS: According to the current use of each conventional care regimens options in Spain, azacitidine resulted in €34,673 per quality-adjusted life-year gained (€28,891 per life-year gained) with an increase of 1.89 in quality-adjusted life-years (2.26 in life-years). Azacitidine was superior to best supportive care and low dose chemotherapy in terms of quality-adjusted life-years gained, 1.82 and 2.03, respectively (life-years 2.16 vs. best supportive care, 2.39 vs. low dose chemotherapy). Treatment with azacitidine resulted in longer survival time and thus longer treatment time and lifetime costs. The incremental cost-effectiveness ratio was €39,610 per quality-adjusted life-year gained vs. best supportive care and €30,531 per quality-adjusted life-year gained vs. low dose chemotherapy (€33,111 per life-year gained vs. best supportive care and €25,953 per life-year gained vs. low dose chemotherapy).

CONCLUSIONS: The analysis showed that the use of azacitidine in the treatment of high-risk myelodysplastic syndrome is a cost-effective option compared with conventional care regimen options used in the Spanish setting and had an incremental cost-effectiveness ratio within the range of the thresholds accepted by health authorities.

References

1. Appl Health Econ Health Policy. 2011 Jul 1;9(4):275-9 - PubMed
2. Ann Hematol. 1992 Oct;65(4):162-8 - PubMed
3. Pharmacoeconomics. 2005;23(5):515-26 - PubMed
4. Value Health. 2012 May;15(3):540-9 - PubMed
5. Clin Transl Oncol. 2008 Dec;10(12):831-9 - PubMed
6. J Med Econ. 2012;15(1):145-54 - PubMed
7. Blood. 2004 Apr 15;103(8):2908-13 - PubMed
8. Health Econ Policy Law. 2012 Oct;7(4):393-409 - PubMed
9. Value Health. 2009 Jan-Feb;12(1):167-71 - PubMed
10. Int J Hematol. 2001 Jun;73(4):405-410 - PubMed
11. Blood. 1997 Mar 15;89(6):2079-88 - PubMed
12. Lancet Oncol. 2009 Mar;10(3):223-32 - PubMed
13. Value Health. 2012 Sep-Oct;15(6):835-42 - PubMed
14. Haematologica. 2002 Dec;87(12):1286-306 - PubMed
15. J Clin Oncol. 2002 May 15;20(10):2429-40 - PubMed
16. Leukemia. 2004 Apr;18(4):809-16 - PubMed
17. Med Decis Making. 2006 Jan-Feb;26(1):18-29 - PubMed
18. Haematologica. 2003 Oct;88(10):1197-9 - PubMed
19. Value Health. 2010 Jan-Feb;13(1):61-8 - PubMed
20. Mayo Clin Proc. 2006 Jan;81(1):104-30 - PubMed
21. BMJ. 2005 Oct 29;331(7523):1019-21 - PubMed
22. J Clin Oncol. 2002 May 15;20(10):2441-52 - PubMed
23. Am J Respir Crit Care Med. 2003 May 15;167(10):1387-92 - PubMed

Publication Types

• Journal Article